PDF(Pubmed)
Abstract：
UNASSIGNED: Radiation-induced lung injury (RILI) is often found in thoracic tumor patients after thoracic radiation therapy, and influences patient quality of life. However, systematic exploration of RILI, including its molecular biological mechanisms and standardized treatment, has not yet been fully elucidated. The main objective of the narrative review was to describe the available evidence concerning RILI, from the biological mechanism to the clinical management. The underlying causes of RILI are multifactorial, including gene-level changes, the influence of signaling pathways, the convergence of various cells, as well as the expression of cytokines and chemokines. Based on the various mechanisms of RILI, several novel treatment strategies have been proposed and gradually applied in clinical practice.
UNASSIGNED: PubMed was used to collect articles about RILI from 1995 to 2021. The papers included clinical trials, reviews, as well as systematic reviews and meta-analyses. Based on the mechanism, diagnosis, and treatment, we synthesized and analyzed these papers to form a clearly logical and normative suggestion to guide clinical application.
UNASSIGNED: RILI is a constantly developing and changing process including radiation pneumonitis and radiation lung fibrosis. Different kinds of inflammatory and immune cells such as macrophages, fibroblasts, and T cells play key roles in the development of RILI, and transforming growth factor-β (TGF-β), interleukin-4 (IL-4), IL-13, and interferon-γ (IFN-γ) are also participants in this process. At present, glucocorticoids are mainly therapeutic drugs for the early stage of RILI, and drugs treatment should abide early period, sufficient doses, and the individual principles. Other novel drugs such as Azithromycin also have been tried in clinical application. radiation dose, combination therapy modality, the condition of the tumor, and the age and underlying conditions of patients all effect the occurrence of RILI. Importantly, RILI has a relatively higher incidence in patients who received radiotherapy combined with other treatments, especially immunotherapy.
UNASSIGNED: The occurrence of RILI after radiotherapy will greatly affect the prognosis and quality of life of patients. In clinical practice, early intervention, active treatment, and more effective therapeutic drugs should be found.
UNASSIGNED: PubMed was used to collect articles about RILI from 1995 to 2021. The papers included clinical trials, reviews, as well as systematic reviews and meta-analyses. Based on the mechanism, diagnosis, and treatment, we synthesized and analyzed these papers to form a clearly logical and normative suggestion to guide clinical application.
UNASSIGNED: RILI is a constantly developing and changing process including radiation pneumonitis and radiation lung fibrosis. Different kinds of inflammatory and immune cells such as macrophages, fibroblasts, and T cells play key roles in the development of RILI, and transforming growth factor-β (TGF-β), interleukin-4 (IL-4), IL-13, and interferon-γ (IFN-γ) are also participants in this process. At present, glucocorticoids are mainly therapeutic drugs for the early stage of RILI, and drugs treatment should abide early period, sufficient doses, and the individual principles. Other novel drugs such as Azithromycin also have been tried in clinical application. radiation dose, combination therapy modality, the condition of the tumor, and the age and underlying conditions of patients all effect the occurrence of RILI. Importantly, RILI has a relatively higher incidence in patients who received radiotherapy combined with other treatments, especially immunotherapy.
UNASSIGNED: The occurrence of RILI after radiotherapy will greatly affect the prognosis and quality of life of patients. In clinical practice, early intervention, active treatment, and more effective therapeutic drugs should be found.
摘要：
未经证实：胸部肿瘤患者在接受胸部放射治疗后经常发生放射性肺损伤（RILI），影响患者的生活质量。然而,对RILI的系统探索，包括其分子生物学机制和标准化治疗，尚未完全阐明。叙述性审查的主要目的是描述有关RILI的现有证据，从生物学机制到临床管理。RILI的根本原因是多方面的，包括基因水平的变化，信号通路的影响，各种细胞的融合，以及细胞因子和趋化因子的表达。基于RILI的各种机制，已经提出了几种新的治疗策略，并逐渐应用于临床实践。
UNASSIGNED：PubMed用于收集1995年至2021年有关RILI的文章。这些论文包括临床试验，reviews,以及系统评价和荟萃分析。基于机制,诊断,和治疗,我们对这些论文进行了综合和分析，以形成清晰的逻辑和规范的建议，以指导临床应用。
UNASSIGNED：RILI是一个不断发展和变化的过程，包括放射性肺炎和放射性肺纤维化。不同种类的炎症和免疫细胞，如巨噬细胞，成纤维细胞,T细胞在RILI的发育中起关键作用，和转化生长因子-β（TGF-β），白细胞介素-4（IL-4），IL-13和干扰素-γ(IFN-γ)也是该过程的参与者。目前,糖皮质激素是RILI早期的主要治疗药物，药物治疗应坚持早期，足够的剂量,和个人原则。其他新药如阿奇霉素也已尝试在临床应用。辐射剂量,联合治疗模式，肿瘤的状况，患者的年龄和基本状况都会影响RILI的发生。重要的是,RILI在接受放疗联合其他治疗的患者中发病率相对较高，尤其是免疫疗法。
UNASSIGNED：放疗后RILI的发生将极大地影响患者的预后和生活质量。在临床实践中,早期干预,积极治疗,应该找到更有效的治疗药物。
UNASSIGNED：PubMed用于收集1995年至2021年有关RILI的文章。这些论文包括临床试验，reviews,以及系统评价和荟萃分析。基于机制,诊断,和治疗,我们对这些论文进行了综合和分析，以形成清晰的逻辑和规范的建议，以指导临床应用。
UNASSIGNED：RILI是一个不断发展和变化的过程，包括放射性肺炎和放射性肺纤维化。不同种类的炎症和免疫细胞，如巨噬细胞，成纤维细胞,T细胞在RILI的发育中起关键作用，和转化生长因子-β（TGF-β），白细胞介素-4（IL-4），IL-13和干扰素-γ(IFN-γ)也是该过程的参与者。目前,糖皮质激素是RILI早期的主要治疗药物，药物治疗应坚持早期，足够的剂量,和个人原则。其他新药如阿奇霉素也已尝试在临床应用。辐射剂量,联合治疗模式，肿瘤的状况，患者的年龄和基本状况都会影响RILI的发生。重要的是,RILI在接受放疗联合其他治疗的患者中发病率相对较高，尤其是免疫疗法。
UNASSIGNED：放疗后RILI的发生将极大地影响患者的预后和生活质量。在临床实践中,早期干预,积极治疗,应该找到更有效的治疗药物。
